Hi On the other side of pain, is progress!And I'm delighted to share every ounce of pain has been worth it with our recent progress in the development and commercialisation of MindBio's Voice AI drug and alcohol intoxication detection technology deve...

Hi I announce this news a little earlier than planned. The initial results are in and its not what we expected!Surprised, Disappointed. Indeed. But the Work Continues......I'm very surprised and as you can imagine, as a founder hopeful to be doing so...

Hi The journey to bring a new mental health treatment to market is a marathon, but the potential of MindBio Therapeutics’ lead candidate, MB22001 as a scalable and patient accessible take-home microdose form of a psychedelic medicine, makes it all wo...

Hi The journey to bring a new mental health treatment to market is a marathon, but the potential of MindBio Therapeutics’ lead candidate, MB22001 as a scalable and patient accessible take-home microdose form of a psychedelic medicine, makes it all wo...

Hi The journey to bring a new mental health treatment to market is a marathon, but the potential of MindBio Therapeutics’ lead candidate, MB22001 as a scalable and patient accessible take-home microdose form of a psychedelic medicine, makes it all wo...

CEO Justin Hanka provides update on Phase 2B clinical trials.

Dr Rachael Sumner discusses Microdosing MB22001 for negative mood symptom relief in Pre-Menstrual Syndrome (PMS) and Pre-Menstrual Dysphoric Disorder (PMDD).

Here is the link to the clinical trial paper on Sleep produced by MindBio scientific collaborators and published in Nature’s portfolio journal Translational Psychiatry:https://www.nature.com/articles/s41398-024-02900-4